Valuation: Alterity Therapeutics Limited

Market Cap 62.64M 55.64M 52.03M 47.41M 89.26M 6.03B 90.49M 629M 244M 3.07B 235M 230M 9.87B P/E 2027 *
-3x
P/E 2028 * -0.37x
Enterprise Value 21.74M 19.31M 18.05M 16.45M 30.97M 2.09B 31.4M 218M 84.55M 1.07B 81.61M 79.84M 3.42B EV / Sales 2027 *
45.7x
EV / Sales 2028 * 12.9x
Free-Float
97.02%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Alterity Therapeutics Limited

1 day+14.29%
3 months+627.27%
6 months+627.27%
Current year+28.00%
Current year 0.01
Extreme 0.01
0.55
1 year 0.01
Extreme 0.01
0.55
3 years 0.01
Extreme 0.01
0.7
5 years 0.01
Extreme 0.01
2.36
10 years 0
Extreme 0.005
3.5
Manager TitleAgeSince
Chief Executive Officer 65 07/01/2021
Director of Finance/CFO - 30/09/2024
Chief Tech/Sci/R&D Officer - 01/04/2019
Director TitleAgeSince
Director/Board Member 70 29/07/2005
Director/Board Member 47 08/08/2011
Director/Board Member 65 21/11/2025
Change 5-day change 1-year change 3-year change Capi.($)
+14.29%-.--% - - 62.64M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.07%-1.51%+24.46%+78.24% 59.26B
+0.68%-0.42%+4.50%+34.79% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average +0.92%-0.52%+52.86%+154.11% 43.6B
Weighted average by Cap. -0.02%-0.32%+58.04%+145.80%

Financials

2027 *2028 *
Net sales 475K 422K 395K 360K 677K 45.77M 687K 4.78M 1.85M 23.31M 1.78M 1.75M 74.88M 1.98M 1.76M 1.64M 1.5M 2.82M 190M 2.86M 19.88M 7.7M 97.01M 7.43M 7.27M 312M
Net income -27.44M -24.38M -22.8M -20.77M -39.11M -2.64B -39.65M -276M -107M -1.35B -103M -101M -4.32B -30.75M -27.31M -25.54M -23.28M -43.82M -2.96B -44.42M -309M -120M -1.51B -115M -113M -4.84B
Net Debt -40.9M -36.33M -33.97M -30.96M -58.29M -3.94B -59.09M -411M -159M -2.01B -154M -150M -6.44B -37.15M -33M -30.86M -28.12M -52.94M -3.58B -53.67M -373M -145M -1.82B -139M -136M -5.85B
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
11
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.4100AUD
Average target price
5.517AUD
Spread / Average Target
+1,245.53%

Quarterly revenue - Rate of surprise